Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy

Inclusion Criteria * Patients must be 55 years of age or older. * Males and females. Females must be of non-childbearing potential (i.e. surgically sterilized or at least one year post-menopausal). * Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of CAA-Related Hemorrhage. * Nonfatal lobar hemorrhage (defined as hemorrhage in the cerebral cortex and underlying white matter sparing the basal ganglia and thalamus) within previous five years diagnosed by CT or MRI scan. * Patient has no intent to donate blood for 4 weeks after completion of the study. * Signed informed consent. Exclusion Criteria * Other established causes of hemorrhage at the time of the index hemorrhage event. Exclusion causes include excessive anticoagulation (INR \> 4.0), associated head trauma or ischemic stroke, CNS tumor, vascular malformation, vasculitis, and blood dyscrasia. * Patient with a clinically significant and uncontrolled cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, hematological condition or other significant medical disease. * Presence of any condition that could interfere with the interpretation of study results or compromise patient safety. * Debilitated neurological state or other known disease likely to result in early death. * Disability characterized by a modified Rankin score ≥ 4. * ALT, ALP, AST or total bilirubin ≥ 1.5 the upper limit of normal ranges. * Contraindications to MRI scan (e.g. cranial metallic implant, cardiac pacemaker, and severe claustrophobia). * Allergy and/or hypersensitivity to analgesic agents used for the lumbar puncture (for patients undergoing lumbar puncture only). * Allergy and/or hypersensitivity to any component of the study medication. * Use of an investigational drug within 30 days prior to Screening visit. * Use of warfarin or warfarin containing compounds and heparin or heparin containing compounds within 7 days prior to Baseline (Week 0) visit. * Diagnosis of cystatin C amyloid angiopathy. * Active alcohol and/or drug abuse. * Inability to provide legal consent